LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Health & Fitness
• Education
• Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cancer, breast, article, google, scholar, cas, advanced, oncol, hormone, therapy, endocrine, metastatic, palbociclib, receptorpositive, metaanalysis, treatment, phase, cdk, inhibitors, carlo, receptor, clin, letrozole, harbeck, fulvestrant, systematic, review, randomized, messina, trial, patients, res, study, paloma, women, analysis, data, trials, hrher, clinical, pubmed, access, human, rugo, hernegative, iwata, ann, privacy, cookies, content,

Topics {✒️}

anti-cancer therapies patient-reported health-related quality hr+/her2− breast cancer metastatic breast cancer advanced breast cancer month download article/chapter hormone receptor-positive hormone-receptor-positive prior endocrine therapy-safety breast cancer statistics breast cancer markers de la cruz-merino randomized clinical trials oestrogen receptor-positive endocrine resistance �� g3–g4 adverse events her2-negative related subjects targeted agents full article pdf cyclin-dependent kinase 4 privacy choices/manage cookies objective response rates breast cancer phase iii trial phase iii study cyclin-dependent kinases patient-reported outcomes author information authors versus endocrine therapy previous endocrine therapy receiving endocrine therapy randomized trials g3–g4 neutropenia check access instant access clinical trials carlo cattrini finn rs systematic literature search initial endocrine therapy cost-utility analysis endocrine-resistant population endocrine-resistant setting van kampen rj van den berkmortel initial palliative therapy conditions privacy policy adding cdk4/6 inhibitors random-effects model

Schema {🗺️}

WebPage:
      mainEntity:
         headline:CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
         description:Combining CDK4/6 inhibitors and endocrine therapy (ET) improved outcomes for the treatment of metastatic HR+/HER2− breast cancers. Here, we performed a meta-analysis of randomized clinical trials (RCTs) to better define the benefit and the risk of CDK4/6 inhibitors plus ET for endocrine-sensitive or endocrine-resistant population in metastatic HR+/HER2− breast cancer. A systematic literature search of Pubmed, Embase, and the Cochrane Library was carried out up to 30 June 2018. Hazard ratios (HRs) and 95% confidence intervals (CIs) for progression-free survival (PFS), as well as odds ratios (ORs) for objective response rates, ≥ G3–G4 adverse events (AEs), and G3–G4 neutropenia were calculated for each trial. A meta-analysis was carried out using the random-effects model. Eight RCTs were eligible including 4578 breast cancer patients. Adding CDK4/6 inhibitors to ET in endocrine-sensitive (HR 0.55, 95% CI 0.50–0.62) or endocrine-resistant setting (HR 0.51, 95% CI 0.43–0.61) significantly improved the PFS of metastatic HR+/HER2− breast cancers regardless of menopausal status and site of metastasis. Moreover, CDK4/6 inhibitors plus ET meaningfully improved objective response rate in endocrine-sensitive (ORs 0.62, 95% CI 0.52–0.73) or endocrine-resistant setting (ORs 0.33, 95% CI 0.24–0.47). The use of these drugs was characterized by a significant increase of G3–G4 AEs (OR 10.88, 95% CI 6.53–18.14). Emerging data provide a new standard treatment for advanced HR+/HER2− breast cancer, regardless of menopausal status, prior hormonal/chemotherapy treatments delivered, sites of metastasis. However, benefits should be balanced with longer treatment duration, toxicities, and costs.
         datePublished:2018-07-27T00:00:00Z
         dateModified:2018-07-27T00:00:00Z
         pageStart:9
         pageEnd:21
         sameAs:https://doi.org/10.1007/s10549-018-4901-0
         keywords:
            Abemaciclib
            Ribociclib
            Palbociclib
            Hormonal therapy
            Breast cancer
            Meta-analysis
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig6_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:172
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Carlo Messina
               url:http://orcid.org/0000-0002-7934-1419
               affiliation:
                     name:Policlinico Hospital San Martino-IST
                     address:
                        name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Genoa
                     address:
                        name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Carlo Cattrini
               affiliation:
                     name:Policlinico Hospital San Martino-IST
                     address:
                        name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Genoa
                     address:
                        name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Giulia Buzzatti
               affiliation:
                     name:Policlinico Hospital San Martino-IST
                     address:
                        name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Genoa
                     address:
                        name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Luigi Cerbone
               affiliation:
                     name:Policlinico Hospital San Martino-IST
                     address:
                        name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Genoa
                     address:
                        name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elisa Zanardi
               affiliation:
                     name:Policlinico Hospital San Martino-IST
                     address:
                        name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Genoa
                     address:
                        name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marco Messina
               affiliation:
                     name:Istituto Fondazione G. Giglio
                     address:
                        name:Oncology Unit, Istituto Fondazione G. Giglio, Cefalù, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Francesco Boccardo
               affiliation:
                     name:Policlinico Hospital San Martino-IST
                     address:
                        name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                        type:PostalAddress
                     type:Organization
                     name:University of Genoa
                     address:
                        name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
      description:Combining CDK4/6 inhibitors and endocrine therapy (ET) improved outcomes for the treatment of metastatic HR+/HER2− breast cancers. Here, we performed a meta-analysis of randomized clinical trials (RCTs) to better define the benefit and the risk of CDK4/6 inhibitors plus ET for endocrine-sensitive or endocrine-resistant population in metastatic HR+/HER2− breast cancer. A systematic literature search of Pubmed, Embase, and the Cochrane Library was carried out up to 30 June 2018. Hazard ratios (HRs) and 95% confidence intervals (CIs) for progression-free survival (PFS), as well as odds ratios (ORs) for objective response rates, ≥ G3–G4 adverse events (AEs), and G3–G4 neutropenia were calculated for each trial. A meta-analysis was carried out using the random-effects model. Eight RCTs were eligible including 4578 breast cancer patients. Adding CDK4/6 inhibitors to ET in endocrine-sensitive (HR 0.55, 95% CI 0.50–0.62) or endocrine-resistant setting (HR 0.51, 95% CI 0.43–0.61) significantly improved the PFS of metastatic HR+/HER2− breast cancers regardless of menopausal status and site of metastasis. Moreover, CDK4/6 inhibitors plus ET meaningfully improved objective response rate in endocrine-sensitive (ORs 0.62, 95% CI 0.52–0.73) or endocrine-resistant setting (ORs 0.33, 95% CI 0.24–0.47). The use of these drugs was characterized by a significant increase of G3–G4 AEs (OR 10.88, 95% CI 6.53–18.14). Emerging data provide a new standard treatment for advanced HR+/HER2− breast cancer, regardless of menopausal status, prior hormonal/chemotherapy treatments delivered, sites of metastasis. However, benefits should be balanced with longer treatment duration, toxicities, and costs.
      datePublished:2018-07-27T00:00:00Z
      dateModified:2018-07-27T00:00:00Z
      pageStart:9
      pageEnd:21
      sameAs:https://doi.org/10.1007/s10549-018-4901-0
      keywords:
         Abemaciclib
         Ribociclib
         Palbociclib
         Hormonal therapy
         Breast cancer
         Meta-analysis
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-018-4901-0/MediaObjects/10549_2018_4901_Fig6_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:172
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Carlo Messina
            url:http://orcid.org/0000-0002-7934-1419
            affiliation:
                  name:Policlinico Hospital San Martino-IST
                  address:
                     name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Genoa
                  address:
                     name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Carlo Cattrini
            affiliation:
                  name:Policlinico Hospital San Martino-IST
                  address:
                     name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Genoa
                  address:
                     name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Giulia Buzzatti
            affiliation:
                  name:Policlinico Hospital San Martino-IST
                  address:
                     name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Genoa
                  address:
                     name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Luigi Cerbone
            affiliation:
                  name:Policlinico Hospital San Martino-IST
                  address:
                     name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Genoa
                  address:
                     name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elisa Zanardi
            affiliation:
                  name:Policlinico Hospital San Martino-IST
                  address:
                     name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Genoa
                  address:
                     name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marco Messina
            affiliation:
                  name:Istituto Fondazione G. Giglio
                  address:
                     name:Oncology Unit, Istituto Fondazione G. Giglio, Cefalù, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Francesco Boccardo
            affiliation:
                  name:Policlinico Hospital San Martino-IST
                  address:
                     name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
                     type:PostalAddress
                  type:Organization
                  name:University of Genoa
                  address:
                     name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:172
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Policlinico Hospital San Martino-IST
      address:
         name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
         type:PostalAddress
      name:University of Genoa
      address:
         name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
         type:PostalAddress
      name:Policlinico Hospital San Martino-IST
      address:
         name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
         type:PostalAddress
      name:University of Genoa
      address:
         name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
         type:PostalAddress
      name:Policlinico Hospital San Martino-IST
      address:
         name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
         type:PostalAddress
      name:University of Genoa
      address:
         name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
         type:PostalAddress
      name:Policlinico Hospital San Martino-IST
      address:
         name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
         type:PostalAddress
      name:University of Genoa
      address:
         name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
         type:PostalAddress
      name:Policlinico Hospital San Martino-IST
      address:
         name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
         type:PostalAddress
      name:University of Genoa
      address:
         name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
         type:PostalAddress
      name:Istituto Fondazione G. Giglio
      address:
         name:Oncology Unit, Istituto Fondazione G. Giglio, Cefalù, Italy
         type:PostalAddress
      name:Policlinico Hospital San Martino-IST
      address:
         name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
         type:PostalAddress
      name:University of Genoa
      address:
         name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Carlo Messina
      url:http://orcid.org/0000-0002-7934-1419
      affiliation:
            name:Policlinico Hospital San Martino-IST
            address:
               name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
               type:PostalAddress
            type:Organization
            name:University of Genoa
            address:
               name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Carlo Cattrini
      affiliation:
            name:Policlinico Hospital San Martino-IST
            address:
               name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
               type:PostalAddress
            type:Organization
            name:University of Genoa
            address:
               name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
               type:PostalAddress
            type:Organization
      name:Giulia Buzzatti
      affiliation:
            name:Policlinico Hospital San Martino-IST
            address:
               name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
               type:PostalAddress
            type:Organization
            name:University of Genoa
            address:
               name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
               type:PostalAddress
            type:Organization
      name:Luigi Cerbone
      affiliation:
            name:Policlinico Hospital San Martino-IST
            address:
               name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
               type:PostalAddress
            type:Organization
            name:University of Genoa
            address:
               name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
               type:PostalAddress
            type:Organization
      name:Elisa Zanardi
      affiliation:
            name:Policlinico Hospital San Martino-IST
            address:
               name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
               type:PostalAddress
            type:Organization
            name:University of Genoa
            address:
               name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
               type:PostalAddress
            type:Organization
      name:Marco Messina
      affiliation:
            name:Istituto Fondazione G. Giglio
            address:
               name:Oncology Unit, Istituto Fondazione G. Giglio, Cefalù, Italy
               type:PostalAddress
            type:Organization
      name:Francesco Boccardo
      affiliation:
            name:Policlinico Hospital San Martino-IST
            address:
               name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
               type:PostalAddress
            type:Organization
            name:University of Genoa
            address:
               name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
      name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
      name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
      name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
      name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
      name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
      name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
      name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
      name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
      name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
      name:Oncology Unit, Istituto Fondazione G. Giglio, Cefalù, Italy
      name:Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy
      name:Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(113)

• How much does https://www.springernature.com/gp/authors pull in monthly?
• Check the income stats for https://link.springernature.com/home/
• How much cash flow does https://order.springer.com/public/cart have monthly?
• What's the monthly income of https://submission.springernature.com/new-submission/10549/3?
• Learn how profitable https://orcid.org/0000-0002-7934-1419 is on a monthly basis
• What's the financial outcome of https://www.springernature.com/gp/librarians/licensing/agc/journals?
• Learn about the earnings of https://doi.org/10.3322%2Fcaac.21412
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Breast%20cancer%20statistics%2C%202017%2C%20racial%20disparity%20in%20mortality%20by%20state&journal=CA%20Cancer%20J%20Clin&doi=10.3322%2Fcaac.21412&volume=67&issue=6&pages=439-448&publication_year=2017&author=DeSantis%2CCE&author=Ma%2CJ&author=Goding%20Sauer%2CA&author=Newman%2CLA&author=Jemal%2CA
• How much does https://doi.org/10.1002%2Fcncr.21359 make?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Survival%20of%20metastatic%20breast%20carcinoma%20patients%20over%20a%2020-year%20period%3A%20a%20retrospective%20analysis%20based%20on%20individual%20patient%20data%20from%20six%20consecutive%20studies&journal=Cancer&doi=10.1002%2Fcncr.21359&volume=104&issue=8&pages=1742-1750&publication_year=2005&author=Gennari%2CA&author=Conte%2CP&author=Rosso%2CR&author=Orlandini%2CC&author=Bruzzi%2CP produce monthly?
• How much profit is https://doi.org/10.1200%2FJCO.2011.37.2482 making per month?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Clinically%20used%20breast%20cancer%20markers%20such%20as%20estrogen%20receptor%2C%20progesterone%20receptor%2C%20and%20human%20epidermal%20growth%20factor%20receptor%202%20are%20unstable%20throughout%20tumor%20progression&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2011.37.2482&volume=30&issue=21&pages=2601-2608&publication_year=2012&author=Lindstr%C3%B6m%2CLS&author=Karlsson%2CE&author=Wilking%2CUM&author=Johansson%2CU&author=Hartman%2CJ&author=Lidbrink%2CEK&author=Hatschek%2CT&author=Skoog%2CL&author=Bergh%2CJ?
• How much does https://doi.org/10.1200%2FJOP.2016.012914 bring in each month?
• What is the monthly revenue of http://scholar.google.com/scholar_lookup?&title=Endocrine%20therapy%20for%20hormone%20receptor%20positive%20metastatic%20breast%20cancer%3A%20American%20Society%20of%20Clinical%20Oncology%20Guideline%20summary&journal=J%20Oncol%20Pract&doi=10.1200%2FJOP.2016.012914&volume=12&issue=6&pages=583-587&publication_year=2016&author=Rugo%2CHS&author=Rumble%2CRB&author=Burstein%2CHJ?
• What's the profit of https://doi.org/10.1146%2Fannurev-med-070909-182917?
• Get to know http://scholar.google.com/scholar_lookup?&title=Mechanisms%20of%20endocrine%20resistance%20in%20breast%20cancer&journal=Annu%20Rev%20Med&doi=10.1146%2Fannurev-med-070909-182917&volume=62&pages=233-247&publication_year=2011&author=Osborne%2CCK&author=Schiff%2CR's earnings
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Targeting%20the%20cyclin-dependent%20kinases%20%28CDK%294%2F6%20in%20estrogen%20receptor-positive%20breast%20cancers&journal=Breast%20Cancer%20Res&doi=10.1186%2Fs13058-015-0661-5&volume=18&issue=1&publication_year=2016&author=Finn%2CRS&author=Aleshin%2CA&author=Slamon%2CDJ
• https://doi.org/10.1016%2FS1470-2045%2814%2971159-3's total income per month
• How much revenue does http://scholar.google.com/scholar_lookup?&title=The%20cyclin-dependent%20kinase%204%2F6%20inhibitor%20palbociclib%20in%20combination%20with%20letrozole%20versus%20letrozole%20alone%20as%20first%20line%20treatment%20of%20oestrogen%20receptor-positive%2C%20HER2-negative%2C%20advanced%20breast%20cancer%20%28PALOMA-1%2FTRIO-18%29%3A%20a%20randomised%20phase%202%20study&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2814%2971159-3&volume=16&issue=1&pages=25-35&publication_year=2015&author=Finn%2CRS&author=Crown%2CJP&author=Lang%2CI&author=Boer%2CK&author=Bondarenko%2CIM&author=Kulyk%2CSO&author=Ettl%2CJ&author=Patel%2CR&author=Pinter%2CT&author=Schmidt%2CM generate?
• Profit of https://doi.org/10.1056%2FNEJMoa1607303
• What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Palbociclib%20and%20letrozole%20in%20advanced%20breast%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1607303&volume=375&issue=20&pages=1925-1936&publication_year=2016&author=Finn%2CRS&author=Martin%2CM&author=Rugo%2CHS&author=Jones%2CS&author=Im%2CS-A&author=Gelmon%2CK&author=Harbeck%2CN&author=Lipatov%2CON&author=Walshe%2CJM&author=Moulder%2CS&author=Gauthier%2CE&author=Lu%2CDR&author=Randolph%2CS&author=Di%C3%A9ras%2CV&author=Slamon%2CDJ?
• What's the total monthly financial gain of https://doi.org/10.1056%2FNEJMoa1609709?
• http://scholar.google.com/scholar_lookup?&title=Ribociclib%20as%20first-line%20therapy%20for%20HR-positive%2C%20advanced%20breast%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1609709&volume=375&issue=18&pages=1738-1748&publication_year=2016&author=Hortobagyi%2CGN&author=Stemmer%2CSM&author=Burris%2CHA&author=Yap%2CYS&author=Sonke%2CGS&author=Paluch-Shimon%2CS&author=Campone%2CM&author=Blackwell%2CKL&author=Andre%2CF&author=Winer%2CEP&author=Janni%2CW's total income per month
• Income figures for https://doi.org/10.1016%2FS1470-2045%2815%2900613-0
• How much income does http://scholar.google.com/scholar_lookup?&title=Fulvestrant%20plus%20palbociclib%20versus%20fulvestrant%20plus%20placebo%20for%20treatment%20of%20hormone-receptor-positive%2C%20HER2-negative%20metastatic%20breast%20cancer%20that%20progressed%20on%20previous%20endocrine%20therapy%20%28PALOMA-3%29%3A%20final%20analysis%20of%20the%20multicentre%2C%20double-blind%2C%20phase%203%20randomised%20controlled%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2815%2900613-0&volume=17&issue=4&pages=425-439&publication_year=2016&author=Cristofanilli%2CM&author=Turner%2CNC&author=Bondarenko%2CI&author=Ro%2CJ&author=Im%2CS-A&author=Masuda%2CN&author=Colleoni%2CM&author=DeMichele%2CA&author=Loi%2CS&author=Verma%2CS&author=Iwata%2CS&author=Harbeck%2CN&author=Zhang%2CK have?
• Explore the financials of https://doi.org/10.1200%2FJCO.2017.73.7585
• How much profit is http://scholar.google.com/scholar_lookup?&title=MONARCH%202%3A%20abemaciclib%20in%20combination%20with%20fulvestrant%20in%20women%20with%20HR%2B%2FHER2%20advanced%20breast%20cancer%20who%20had%20progressed%20while%20receiving%20endocrine%20therapy&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2017.73.7585&volume=35&issue=25&pages=2875-2884&publication_year=2017&author=Sledge%2CGW&author=Toi%2CM&author=Neven%2CP&author=Sohn%2CJ&author=Inoue%2CK&author=Pivot%2CX&author=Burdaeva%2CO&author=Okera%2CM&author=Masuda%2CN&author=Kaufman%2CPA&author=Koh%2CH&author=Grischke%2CEM&author=Frenzel%2CM&author=Lin%2CY&author=Barriga%2CS&author=Smith%2CIC&author=Bourayou%2CN&author=Llombart-Cussac%2CA making per month?
• What are the total earnings of https://doi.org/10.1200%2FJCO.2017.75.6155?
• How much profit is http://scholar.google.com/scholar_lookup?&title=MONARCH%203%3A%20abemaciclib%20as%20initial%20therapy%20for%20advanced%20breast%20cancer&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2017.75.6155&volume=35&issue=32&pages=3638-3646&publication_year=2017&author=Goetz%2CMP&author=Toi%2CM&author=Campone%2CM&author=Sohn%2CJ&author=Paluch-Shimon%2CS&author=Huober%2CJ&author=Park%2CIH&author=Tr%C3%A9dan%2CO&author=Chen%2CSC&author=Manso%2CL&author=Freedman%2COC&author=Garnica%20Jaliffe%2CG&author=Forrester%2CT&author=Frenzel%2CM&author=Barriga%2CS&author=Smith%2CIC&author=Bourayou%2CN&author=Leo%2CA making per month?
• How much does https://doi.org/10.1016/S1470-2045(18)30292-4 gross monthly?
• What's the financial outcome of https://doi.org/10.1016%2FS1470-2045%2818%2930292-4?
• Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29804902 earns monthly
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Ribociclib%20plus%20endocrine%20therapy%20for%20premenopausal%20women%20with%20hormone-receptor-positive%2C%20advanced%20breast%20cancer%20%28MONALEESA-7%29%3A%20a%20randomised%20phase%203%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2818%2930292-4&publication_year=2018&author=Tripathy%2CD&author=Im%2CSA&author=Colleoni%2CM&author=Franke%2CF&author=Bardia%2CA&author=Harbeck%2CN&author=Hurvitz%2CSA&author=Chow%2CL&author=Sohn%2CJ&author=Lee%2CKS&author=Campos-Gomez%2CS&author=Villanueva%20Vazquez%2CR&author=Jung%2CKH&author=Babu%2CKG&author=Wheatley-Price%2CP&author=Laurentiis%2CM&author=Im%2CYH&author=Kuemmel%2CS&author=El-Saghir%2CN&author=Liu%2CMC&author=Carlson%2CG&author=Hughes%2CG&author=Diaz-Padilla%2CI&author=Germa%2CC&author=Hirawat%2CS&author=Lu%2CYS is on a monthly basis
• How much does https://doi.org/10.1200/JCO.2018.78.9909 net monthly?
• What are the earnings of https://doi.org/10.1200%2FJCO.2018.78.9909?
• What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29860922's gross income?
• What are the total earnings of http://scholar.google.com/scholar_lookup?&title=Phase%20III%20randomized%20study%20of%20ribociclib%20and%20fulvestrant%20in%20hormone%20receptor-positive%2C%20human%20epidermal%20growth%20factor%20receptor%202-negative%20advanced%20breast%20cancer%3A%20MONALEESA-3&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2018.78.9909&publication_year=2018&author=Slamon%2CDJ&author=Neven%2CP&author=Chia%2CS&author=Fasching%2CPA&author=Laurentiis%2CM&author=Im%2CSA&author=Petrakova%2CK&author=Bianchi%2CGV&author=Esteva%2CFJ&author=Mart%C3%ADn%2CM&author=Nusch%2CA&author=Sonke%2CGS&author=Cruz-Merino%2CL&author=Beck%2CJT&author=Pivot%2CX&author=Vidam%2CG&author=Wang%2CY&author=Rodriguez%20Lorenc%2CK&author=Miller%2CM&author=Taran%2CT&author=Jerusalem%2CG?
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Meta-analysis&publication_year=2008&author=Greenland%2CS&author=O%E2%80%99Rourke%2CK?
• What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=13655060?
• See how much http://scholar.google.com/scholar_lookup?&title=Statistical%20aspects%20of%20the%20analysis%20of%20data%20from%20retrospective%20studies%20of%20disease&journal=J%20Natl%20Cancer%20Inst&volume=22&issue=4&pages=719-748&publication_year=1959&author=Mantel%2CN&author=Haenszel%2CW makes per month
• What's the monthly money flow for https://doi.org/10.1002%2Fsim.1186?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Quantifying%20heterogeneity%20in%20a%20meta-analysis&journal=Stat%20Med&doi=10.1002%2Fsim.1186&volume=21&issue=11&pages=1539-1558&publication_year=2002&author=Higgins%2CJP&author=Thompson%2CSG make?
• Learn how profitable https://doi.org/10.1258%2F1355819021927674 is on a monthly basis
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Statistical%20heterogeneity%20in%20systematic%20reviews%20of%20clinical%20trials%3A%20a%20critical%20appraisal%20of%20guidelines%20and%20practice&journal=J%20Health%20Serv%20Res%20Policy&doi=10.1258%2F1355819021927674&volume=7&issue=1&pages=51-61&publication_year=2002&author=Higgins%2CJ&author=Thompson%2CS&author=Deeks%2CJ&author=Altman%2CD?
• What's the total monthly financial gain of https://doi.org/10.1016%2Fj.ejca.2017.08.018?
• http://scholar.google.com/scholar_lookup?&title=Palbociclib%20in%20hormone%20receptor%20positive%20advanced%20breast%20cancer%3A%20a%20cost-utility%20analysis&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2017.08.018&volume=85&pages=146-154&publication_year=2017&author=Raphael%2CJ&author=Helou%2CJ&author=Pritchard%2CKI&author=Naimark%2CDM income
• How much does https://doi.org/10.1200%2FJGO.2016.008318 pull in monthly?
• What's the income of http://scholar.google.com/scholar_lookup?&title=PALOMA-3%3A%20phase%20III%20trial%20of%20fulvestrant%20with%20or%20without%20palbociclib%20in%20premenopausal%20and%20postmenopausal%20women%20with%20hormone%20receptor-positive%2C%20human%20epidermal%20growth%20factor%20receptor%202-negative%20metastatic%20breast%20cancer%20that%20progressed%20on%20prior%20endocrine%20therapy-safety%20and%20efficacy%20in%20Asian%20patients&journal=J%20Glob%20Oncol&doi=10.1200%2FJGO.2016.008318&volume=3&issue=4&pages=289-303&publication_year=2017&author=Iwata%2CH&author=Im%2CSA&author=Masuda%2CN&author=Im%2CYH&author=Inoue%2CK&author=Rai%2CY&author=Nakamura%2CR&author=Kim%2CJH&author=Hoffman%2CJT&author=Zhang%2CK&author=Giorgetti%2CC&author=Iyer%2CS&author=Schnell%2CPT&author=Bartlett%2CCH&author=Ro%2CJ?
• Earnings of https://doi.org/10.1634%2Ftheoncologist.2017-0072
• How much income is http://scholar.google.com/scholar_lookup?&title=Palbociclib%20combined%20with%20fulvestrant%20in%20premenopausal%20women%20with%20advanced%20breast%20cancer%20and%20prior%20progression%20on%20endocrine%20therapy%3A%20PALOMA-3%20results&journal=Oncologist&doi=10.1634%2Ftheoncologist.2017-0072&volume=22&issue=9&pages=1028-1038&publication_year=2017&author=Loibl%2CS&author=Turner%2CNC&author=Ro%2CJ&author=Cristofanilli%2CM&author=Iwata%2CH&author=Im%2CSA&author=Masuda%2CN&author=Loi%2CS&author=Andr%C3%A9%2CF&author=Harbeck%2CN&author=Verma%2CS&author=Folkerd%2CE&author=Puyana%20Theall%2CK&author=Hoffman%2CJ&author=Zhang%2CK&author=Bartlett%2CCH&author=Dowsett%2CM earning monthly?
• Get to know https://doi.org/10.1634%2Ftheoncologist.2016-0097's earnings
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Palbociclib%20in%20combination%20with%20fulvestrant%20in%20women%20with%20hormone%20receptor-positive%2FHER2-negative%20advanced%20metastatic%20breast%20cancer%3A%20detailedsafety%20analysis%20from%20a%20multicenter%2C%20randomized%2C%20placebo-controlled%2C%20phase%20III%20study%20%28PALOMA-3%29&journal=Oncologist&doi=10.1634%2Ftheoncologist.2016-0097&volume=21&issue=10&pages=1165-1175&publication_year=2016&author=Verma%2CS&author=Bartlett%2CCH&author=Schnell%2CP&author=DeMichele%2CAM&author=Loi%2CS&author=Ro%2CJ&author=Colleoni%2CM&author=Iwata%2CH&author=Harbeck%2CN&author=Cristofanilli%2CM&author=Zhang%2CK&author=Thiele%2CA&author=Turner%2CNC&author=Rugo%2CHS?
• What's the profit of https://doi.org/10.1093%2Fannonc%2Fmdw139?
• How much does http://scholar.google.com/scholar_lookup?&title=Quality%20of%20life%20with%20palbociclib%20plus%20fulvestrant%20in%20previously%20treated%20hormone%20receptor-positive%2C%20HER2-negative%20metastatic%20breast%20cancer%3A%20patient-reported%20outcomes%20from%20the%20PALOMA-3%20trial&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdw139&volume=27&issue=6&pages=1047-1054&publication_year=2016&author=Harbeck%2CN&author=Iyer%2CS&author=Turner%2CN&author=Cristofanilli%2CM&author=Ro%2CJ&author=Andr%C3%A9%2CF&author=Loi%2CS&author=Verma%2CS&author=Iwata%2CH&author=Bhattacharyya%2CH&author=Puyana%20Theall%2CK&author=Bartlett%2CCH&author=Loibl%2CS make?
• How much does https://doi.org/10.2147%2FCMAR.S72592 generate monthly?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Management%20of%20patients%20with%20hormone%20receptor-positive%20breast%20cancer%20with%20visceral%20disease%3A%20challenges%20and%20treatment%20options&journal=Cancer%20Manag%20Res&doi=10.2147%2FCMAR.S72592&volume=7&pages=37-46&publication_year=2015&author=Harb%2CWA?
• What is the earnings of https://doi.org/10.1093%2Fannonc%2Fmdv544?
• What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=In%20real%20life%2C%20one-quarter%20of%20patients%20with%20hormone%20receptor-positive%20metastatic%20breast%20cancer%20receive%20chemotherapy%20as%20initial%20palliative%20therapy%3A%20a%20study%20of%20the%20Southeast%20Netherlands%20Breast%20Cancer%20Consortium&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdv544&volume=27&issue=2&pages=256-262&publication_year=2016&author=Lobbezoo%2CDJ&author=Kampen%2CRJ&author=Voogd%2CAC&author=Dercksen%2CMW&author=Berkmortel%2CF&author=Smilde%2CTJ&author=Wouw%2CAJ&author=Peters%2CFP&author=Riel%2CJM&author=Peters%2CNA&author=Boer%2CM&author=Peer%2CPG&author=Tjan-Heijnen%2CVC?
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28177437?
• How much cash flow does http://scholar.google.com/scholar_lookup?&title=3rd%20ESO-ESMO%20International%20Consensus%20Guidelines%20for%20Advanced%20Breast%20Cancer%20%28ABC%203%29&journal=Ann%20Oncol&volume=28&issue=1&pages=16-33&publication_year=2017&author=Cardoso%2CF&author=Costa%2CA&author=Senkus%2CE&author=Aapro%2CM&author=Andr%C3%A9%2CF&author=Barrios%2CCH&author=Bergh%2CJ&author=Bhattacharyya%2CG&author=Biganzoli%2CL&author=Cardoso%2CMJ&author=Carey%2CL&author=Corneliussen-James%2CD&author=Curigliano%2CG&author=Dieras%2CV&author=Saghir%2CN&author=Eniu%2CA&author=Fallowfield%2CL&author=Fenech%2CD&author=Francis%2CP&author=Gelmon%2CK&author=Gennari%2CA&author=Harbeck%2CN&author=Hudis%2CC&author=Kaufman%2CB&author=Krop%2CI&author=Mayer%2CM&author=Meijer%2CH&author=Mertz%2CS&author=Ohno%2CS&author=Pagani%2CO&author=Papadopoulos%2CE&author=Peccatori%2CF&author=Penault-Llorca%2CF&author=Piccart%2CMJ&author=Pierga%2CJY&author=Rugo%2CH&author=Shockney%2CL&author=Sledge%2CG&author=Swain%2CS&author=Thomssen%2CC&author=Tutt%2CA&author=Vorobiof%2CD&author=Xu%2CB&author=Norton%2CL&author=Winer%2CE have monthly?
• Profit of http://scholar.google.com/scholar_lookup?&title=Chemotherapy%20alone%20versus%20endocrine%20therapy%20alone%20for%20metastatic%20breast%20cancer&journal=Cochrane%20Database%20Syst%20Rev&volume=2&publication_year=2003&author=Wilcken%2CN&author=Hornbuckle%2CJ&author=Ghersi%2CD
• How much revenue does http://scholar.google.com/scholar_lookup?&title=The%20association%20of%20chemotherapy%20versus%20hormonal%20therapy%20and%20health%20outcomes%20among%20patients%20with%20hormone%20receptor-positive%2C%20HER2-negative%20metastatic%20breast%20cancer%3A%20experience%20from%20the%20patient%20perspective&journal=Expert%20Rev%20Pharm%20Outcomes%20Res&volume=14&issue=6&pages=929-940&publication_year=2014&author=Gupta%2CS&author=Zhang%2CJ&author=Jerusalem%2CG produce monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Systematic%20review%20and%20network%20meta-analysis%20comparing%20palbociclib%20with%20chemotherapy%20agents%20for%20the%20treatment%20of%20postmenopausal%20women%20with%20HR-positive%20and%20HER2-negative%20advanced%2Fmetastatic%20breast%20cancer&journal=Breast%20Cancer%20Res%20Treat&doi=10.1007%2Fs10549-017-4404-4&volume=166&issue=1&pages=167-177&publication_year=2017&author=Wilson%2CFR&author=Varu%2CA&author=Mitra%2CD&author=Cameron%2CC&author=Iyer%2CS generate monthly?
• What's https://doi.org/10.1016%2Fj.ctrv.2017.09.009's gross income?
• What are the earnings of http://scholar.google.com/scholar_lookup?&title=Risk%20of%20adverse%20events%20with%20the%20addition%20of%20targeted%20agents%20to%20endocrine%20therapy%20in%20patients%20with%20hormone%20receptor-positive%20metastatic%20breast%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis&journal=Cancer%20Treat%20Rev&doi=10.1016%2Fj.ctrv.2017.09.009&volume=62&pages=123-132&publication_year=2018&author=Martel%2CS&author=Bruzzone%2CM&author=Ceppi%2CM&author=Maurer%2CC&author=Ponde%2CNF&author=Ferreira%2CAR&author=Viglietti%2CG&author=Mastro%2CL&author=Prady%2CC&author=Azambuja%2CE&author=Lambertini%2CM?
• What's the financial outcome of https://doi.org/10.1158%2F1078-0432.CCR-15-1421?
• How much does http://scholar.google.com/scholar_lookup?&title=Mechanistic%20investigation%20of%20bone%20marrow%20suppression%20associated%20with%20palbociclib%20and%20its%20differentiation%20from%20cytotoxic%20chemotherapies&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-15-1421&volume=22&issue=8&pages=2000-2008&publication_year=2016&author=Hu%2CW&author=Sung%2CT&author=Jessen%2CBA&author=Thibault%2CS&author=Finkelstein%2CMB&author=Khan%2CNK&author=Sacaan%2CAI earn?
• How much revenue does https://doi.org/10.1093%2Fannonc%2Fmdy012 generate?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=Impact%20of%20palbociclib%20plus%20letrozole%20on%20patient-reported%20health-related%20quality%20of%20life%3A%20results%20from%20the%20PALOMA-2%20trial&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdy012&volume=29&issue=4&pages=888-894&publication_year=2018&author=Rugo%2CHS&author=Di%C3%A9ras%2CV&author=Gelmon%2CKA&author=Finn%2CRS&author=Slamon%2CDJ&author=Martin%2CM&author=Neven%2CP&author=Shparyk%2CY&author=Mori%2CA&author=Lu%2CDR&author=Bhattacharyya%2CH&author=Bartlett%2CCH&author=Iyer%2CS&author=Johnston%2CS&author=Ettl%2CJ&author=Harbeck%2CN
• https://doi.org/10.1200%2FJCO.2018.36.15_suppl.1002 income
• Find out how much http://scholar.google.com/scholar_lookup?&title=Abemaciclib%20for%20pre%2Fperimenopausal%20women%20with%20HR%2B%2C%20HER2-%20advanced%20breast%20cancer&journal=Journal%20of%20Clinical%20Oncology&doi=10.1200%2FJCO.2018.36.15_suppl.1002&volume=36&issue=15_suppl&pages=1002-1002&publication_year=2018&author=Neven%2CPatrick&author=Rugo%2CHope%20S.&author=Tolaney%2CSara%20M.&author=Iwata%2CHiroji&author=Toi%2CMasakazu&author=Goetz%2CMatthew%20P.&author=Kaufman%2CPeter%20A.&author=Barriga%2CSusana&author=Lin%2CYong&author=Sledge%2CGeorge%20W. earns monthly
• https://doi.org/10.1200%2FJCO.2017.35.15_suppl.1001's financial summary
• Income figures for http://scholar.google.com/scholar_lookup?&title=Overall%20survival%20results%20from%20the%20randomized%20phase%20II%20study%20of%20palbociclib%20%28P%29%20in%20combination%20with%20letrozole%20%28L%29%20vs%20letrozole%20alone%20for%20frontline%20treatment%20of%20ER%2B%2FHER2%E2%88%92%20advanced%20breast%20cancer%20%28PALOMA-1%3B%20TRIO-18%29&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2017.35.15_suppl.1001&volume=34&publication_year=2017&author=Finn%2CRS&author=Crown%2CJ&author=Lang%2CI&author=Boer%2CK&author=Bondarenko%2CI&author=Kulyk%2CSO&author=Ettl%2CJ&author=Patel%2CR&author=Pinter%2CT&author=Schmidt%2CM&author=Shparyk%2CYV&author=Thummala%2CA&author=Voytko%2CNL&author=Fowst%2CC&author=Huang%2CX&author=Kim%2CS&author=Slamon%2CDJ
• What's http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29718092's gross income?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Updated%20results%20from%20MONALEESA-2%2C%20a%20phase%20III%20trial%20of%20first-line%20ribociclib%20plus%20letrozole%20versus%20placebo%20plus%20letrozole%20in%20hormone%20receptor-positive%2C%20HER2-negative%20advanced%20breast%20cancer&journal=Ann%20Oncol&volume=29&pages=1541-1547&publication_year=2018&author=Hortobagyi%2CGN&author=Stemmer%2CSM&author=Burris%2CHA&author=Yap%2CYS&author=Sonke%2CGS&author=Paluch-Shimon%2CS&author=Campone%2CM&author=Petrakova%2CK&author=Blackwell%2CKL&author=Winer%2CEP&author=Janni%2CW&author=Verma%2CS&author=Conte%2CP&author=Arteaga%2CCL&author=Cameron%2CDA&author=Mondal%2CS&author=Su%2CF&author=Miller%2CM&author=Elmeliegy%2CM&author=Germa%2CC&author=O%E2%80%99Shaughnessy%2CJ?
• How much does https://doi.org/10.1093%2Fannonc%2Fmdx521 make?
• What's http://scholar.google.com/scholar_lookup?&title=A%20standardised%2C%20generic%2C%20validated%20approach%20to%20stratify%20the%20magnitude%20of%20clinical%20benefit%20that%20can%20be%20anticipated%20from%20anti-cancer%20therapies%3Athe%20European%20Society%20for%20Medical%20Oncology%20Magnitude%20of%20Clinical%20Benefit%20Scale%28ESMO-MCBS%29&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmdx521&volume=28&issue=11&pages=2901-2905&publication_year=2017&author=Cherny%2CNI&author=Sullivan%2CR&author=Dafni%2CU&author=Kerst%2CJM&author=Sobrero%2CA&author=Zielinski%2CC&author=Vries%2CEGE&author=Piccart%2CMJ's gross income?
• How much money does https://doi.org/10.1093%2Fjnci%2Fdjp369 generate?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Detecting%20an%20overall%20survival%20benefit%20that%20is%20derived%20from%20progression-free%20survival&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdjp369&volume=101&issue=23&pages=1642-1649&publication_year=2009&author=Broglio%2CKR&author=Berry%2CDA
• What's https://citation-needed.springer.com/v2/references/10.1007/s10549-018-4901-0?format=refman&flavour=references's gross income?
• What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Carlo%20Messina?
• What's the monthly money flow for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Carlo%20Messina%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Explore the financials of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Carlo%20Cattrini
• How much cash flow does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Carlo%20Cattrini%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have monthly?
• Financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Giulia%20Buzzatti
• What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Giulia%20Buzzatti%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Income figures for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Luigi%20Cerbone
• Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Luigi%20Cerbone%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Elisa%20Zanardi
• Earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Elisa%20Zanardi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Marco%20Messina
• Check the income stats for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Marco%20Messina%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What are the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Francesco%20Boccardo?
• How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Francesco%20Boccardo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
• How much does https://s100.copyright.com/AppDispatchServlet?title=CDK4%2F6%20inhibitors%20in%20advanced%20hormone%20receptor-positive%2FHER2-negative%20breast%20cancer%3A%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20trials&author=Carlo%20Messina%20et%20al&contentID=10.1007%2Fs10549-018-4901-0©right=Springer%20Science%2BBusiness%20Media%2C%20LLC%2C%20part%20of%20Springer%20Nature&publication=0167-6806&publicationDate=2018-07-27&publisherName=SpringerNature&orderBeanReset=true pull in?
• How profitable is https://crossmark.crossref.org/dialog/?doi=10.1007/s10549-018-4901-0?
• How much does https://citation-needed.springer.com/v2/references/10.1007/s10549-018-4901-0?format=refman&flavour=citation earn?
• Check the income stats for https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral
• What are the earnings of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research?
• How much does https://www.springernature.com/gp/products earn?
• What's the monthly income of https://www.springernature.com/gp/librarians?
• How much profit does https://www.springernature.com/gp/societies generate?
• What are the total earnings of https://www.springernature.com/gp/partners?
• What's the income of https://www.springer.com/?
• What's the financial gain of https://www.nature.com/?
• https://www.biomedcentral.com/'s total income per month
• How much income is https://www.palgrave.com/ earning monthly?
• What's the financial gain of https://www.apress.com/?
• What's the monthly money flow for https://www.springernature.com/gp/legal/ccpa?
• How much income does https://www.springernature.com/gp/info/accessibility have?
• See how much https://support.springernature.com/en/support/home makes per month
• What is the earnings of https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations?
• https://www.springernature.com/ income

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref